How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. A Study of Autologous Induced Islet Body With Type 1 Diabetes

Medical Science and Technology Co., Ltd. Information provided by (Responsible Party): Allife Medical Science and Technology Co., Ltd. Study Details Study Description Go to Brief Summary: This is a single centre、single arm、open-label study,to investigate the safety and efficacy of Autologous induced islet body With Type 1 diabetes Condition or disease Intervention/treatment Phase Type 1 Diabetes Biological: islet body Early Phase 1 Study Design Go to Layout table for study information Study Type (...) Inclusion Criteria: Male or female, 18 to 70 years old (including 18 and 70 years old) Diagnosed as type I diabetes, the diagnostic criteria refer to the 1990 WHO diabetes diagnostic criteria: (1)Diabetes symptoms (hyperglycemia caused by polydipsia, polyphagia, weight loss, itchy skin, blurred vision and other acute metabolic disorders) + random blood glucose ≥ 11.1nmol / L; (2)Fasting blood glucose ≥7.0mmol/L or 75g glucose meets 2-hour blood glucose ≥11.1mmol/L. 3、Voluntary informed consent is given

2018 Clinical Trials

182. Prognostic Imaging Biomarkers for Diabetic Kidney Disease

with other measures that predict progression in DKD, and follow patients every year for 3 years (4 years total study participation) to see if the imaging biomarkers predict worsening DKD. Condition or disease Intervention/treatment Diabetic Kidney Disease Diagnostic Test: MRI (magnetic resonance imaging) Diagnostic Test: US (ultrasound) Procedure: Renal Biopsy Diagnostic Test: Positron Emission Tomography (PET) Diagnostic Test: Microvascular Assessment Study Design Go to Layout table for study (...) Diseases Diabetic Nephropathies Urologic Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases

2018 Clinical Trials

183. Autologous Platelets Rich Plasma (APRP) Treatment Vs Saline Dressing for the Management of Diabetic Foot Ulcer

terms Ulcer Diabetic Foot Foot Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases (...) , 2018 Last Update Posted : October 23, 2018 Sponsor: Services Hospital, Lahore Information provided by (Responsible Party): Dr. SamiUllah, Services Hospital, Lahore Study Details Study Description Go to Brief Summary: The aim of this study is to compare between the platelet rich plasma and normal saline dressing in the healing diabetic foot ulcers. It will be a randomized controlled trial. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Other: Autologous Platelets Rich Plasma

2018 Clinical Trials

184. Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

, an effective countermeasure is an urgent unmet medical need. The SGLT2 inhibitors hold exciting promise to address this need. Condition or disease Intervention/treatment Phase Hypertension Diabetes Mellitus, Type 2 Drug: Ertugliflozin Drug: Hydrochlorothiazide 12.5mg Device: Microneurography Other: SKNA recordings Other: Static Handgrip Other: Post-handgrip forearm vascular occlusion Other: Testing of the Arterial Baroreflex Function Phase 4 Study Design Go to Layout table for study information Study Type (...) diabetes mellitus is firmly established as a state of sympathetic neural overactivity, which may contribute to coexistent hypertension, heart failure, sudden cardiac death, macro- and micro-vascular complications of diabetes, and diabetic nephropathy. In patients recently diagnosed with Type 2 diabetes, microelectrode recordings of sympathetic nerve activity (SNA) targeted to the skeletal muscle circulation have shown both: abnormally high resting (ambient) levels of sympathetic nerve activity

2018 Clinical Trials

185. Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

Monitoring System. Condition or disease Intervention/treatment Phase Type2 Diabetes Mellitus Drug: BTI320 Other: Placebo Phase 2 Detailed Description: The objective of the current study is to investigate the efficacy and safety of BTI320 compared to placebo in addition to metformin and/or sulfonylureas on glycemic control over 12 weeks in subjects with type 2 diabetes mellitus. This is a randomized, placebo-controlled, double-blind, multi-center study with two treatment arms. Study duration (...) : August 31, 2018 Last Update Posted : October 22, 2018 See Sponsor: Boston Therapeutics Collaborator: Sugardown Company Limited Information provided by (Responsible Party): Boston Therapeutics Study Details Study Description Go to Brief Summary: The objective of the current study is to investigate the efficacy and safety of BTI320 compared to placebo in addition to metformin and/or sulfonylureas on glycemic control over 12 weeks in subjects with type 2 diabetes mellitus. This is a randomized, placebo

2018 Clinical Trials

186. A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Semaglutide Drug: Insulin aspart Drug: Insulin glargine U100 Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 2043 participants Allocation (...) and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain

2018 Clinical Trials

187. A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

of 2 days to 4 weeks with daily doses of insulin glargine before you start the insulin 287 period. All doses will be injected under the skin. The study will last for about 16 to 24 weeks. The participant will have 27 visits with the study doctor. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: Insulin 287 Drug: IGlar U100 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 66 participants (...) (both inclusive) at the time of signing informed consent Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening Current daily basal insulin treatment greater than or equal to 0.2 U/kg/day Body mass index between 18.5 and 29.0 kg/m^2 (both inclusive) HbA1c less than or equal to 7.5% Exclusion Criteria: History or presence of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal or endocrinological conditions Subjects

2018 Clinical Trials

188. Cutaneous squamous carcinoma in a patient with diabetic foot: an unusual evolution of a frequent complication Full Text available with Trip Pro

(or other ultraviolet radiations), immunosuppression, chronic scarring conditions and some familial cancer syndromes. Although the majority of cSCCs are adequately eradicated by surgical excision, a subgroup of cSCC may be linked with an increased risk of recurrence, metastasis and death. The incidence of type 2 diabetes mellitus is constantly increasing worldwide. Importantly, diabetes mellitus is a strong risk factor for cancers (including cutaneous tumors) and is highly related with poor cancer (...) Cutaneous squamous carcinoma in a patient with diabetic foot: an unusual evolution of a frequent complication After basal cell carcinoma, the cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer worldwide, and, classically, arises from the upper coats of the epidermis of sun-exposed areas or from skin areas constantly exposed to a chronic inflammatory stimulus. The occurrence of cSCC seems to be linked to several factors, including exposure to sunlight

2018 Endocrinology, diabetes & metabolism case reports

189. Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

for their potentially beneficial effect to enhance the vessel formation. Condition or disease Intervention/treatment Diabetes Complications Diabetic Retinopathy Biological: Generation of inducible pluripotent stem cells Detailed Description: Vascular complications due to diabetes mellitus (DM) are the result of sustained vascular injury with insufficient vascular repair. In chronic diabetes, vascular reparative mechanism can be lost resulting in development of microvascular complications (MVC), such as diabetic (...) in the study as a study subject we will require: a) the subject must either carry the diagnosis of diabetes or be a healthy aged control and b) the patient be willing and have the ability to cooperate with the eye exam and skin punch biopsy protocol. Exclusion Criteria: We will apply the following exclusion criteria: a) evidence of ongoing acute or chronic infection (HIV, Hepatitis B or C, tuberculosis); b) ongoing malignancy; c) cerebral vascular accident or cerebral vascular procedure; d) current

2018 Clinical Trials

190. Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:

2019 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Diabetic Foot Foot Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases (...) decreased perfusion and poor oxygenation of tissue.15 The presence of wound hypoxia is an major etiological pathway in the development of chronic non-healing diabetic foot ulcers Condition or disease Intervention/treatment Phase Ulcer Foot Diabetic Foot Ulcer Other: HBOT Behavioral: Standard wound care Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 0 participants Allocation: Randomized Intervention Model: Parallel

2018 Clinical Trials

191. Laser Therapy for At-Home Treatment of Diabetic Foot Ulcers

Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases (...) the effectiveness of B-cure laser, a home-use low-level laser device, for acceleration of diabetic foot ulcer healing over standard treatment. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Device: B-Cure Laser Pro Device: Sham laser Not Applicable Detailed Description: Patients with diabetic foot ulcers will receive standard treatment and in addition will be randomly allocated to receive either active or sham laser device to self treat at home. The patient's wound will be evaluated every

2018 Clinical Trials

192. Laser Therapy for At-Home Treatment of DIabetic Foot Ulcers

Carmel ltd: Photobiomodulation Low-Level Light Therapy Low-Level Laser Therapy Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Diabetic Foot Foot Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases (...) the effectiveness of B-cure laser, a home-use low-level laser (photobiomodulation) device, for acceleration of diabetic foot ulcer healing over standard treatment. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Device: B-Cure Pro Device: Sham Not Applicable Detailed Description: Patients with diabetic foot ulcers will receive standard treatment and in addition will be randomly allocated to receive either active or sham laser device to self-treat at home. The patient's wound

2018 Clinical Trials

193. A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes

pregnant during the study period. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Insulin degludec Drug: Insulin glargine Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 502 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing (...) Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male or female, age greater than or equal to 18 years at the time of signing informed consent Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening Subjects fulfilling at least one of the below criteria: Experienced at least one severe hypoglycaemic episode within the last year prior to screening

2018 Clinical Trials

194. Nicotinamide Riboside for Diabetic Neuropathy

to take an alternative medication to Warfarin or Factor X inhibitors when undergoing a skin biopsy. Neuropathy due to factors other than type 2 diabetes mellitus based on careful clinical and laboratory evaluation by the study physicians. Abnormal liver function tests, including alanine transaminase, aspartate transaminase, alkaline phosphatase, and bilirubin. Current severe medical conditions that are active on the day of screening. Contacts and Locations Go to Information from the National Library (...) -ribofuranosyl-pyridinium chloride - NR) as a potential therapy for diabetic neuropathy. Phase I data indicates safety in humans. This study seeks to investigate the use of Niagen® (NR) as a potential treatment for diabetic neuropathy in subjects with type 2 diabetes mellitus or impaired glucose tolerance over a 6 month period. The endpoint measures in addition to the IENFD with determine changes in clinical and electrophysiological outcomes, quality of life and biochemical measures. Condition or disease

2018 Clinical Trials

195. Nutritional Supplement on Wound Healing in Diabetic Foot

: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Diabetic Foot Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Foot Ulcer Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies (...) ) that binds native chromatin and bookmarks genomic regions for transcriptional activity may play a role in nutritional supplements in acute stressed diabetic patients. Therefore, we intend to conduct a pilot study on the for FOXA2 gene in maintaining glucose homeostasis in diabetic foot patients after nutritional interventions. Condition or disease Intervention/treatment Phase Diabetic Foot Dietary Supplement: Abound Not Applicable Study Design Go to Layout table for study information Study Type

2018 Clinical Trials

196. Propolis as Adjuvant in the Healing of Human Diabetic Foot Wounds

are in treatment with cures and who meet the following criteria. inclusion: People with Diabetes Mellitus (DM), older than 18 years, type 1 or 2, with known evolution of their diabetes between 2 and 15 years. Carriers of diabetic foot ulcers Without other important diseases Patients who present the following criteria will be excluded from the study: Propolis allergy Serious circulation problems Foot burns Psychological conditions, or distances that prevent regular attendance to all required cures. According (...) that among the benefits produced by Propolis, is its anti-inflammatory, antioxidant effect and that the topical application of it is well tolerated, improving the healing of human diabetic foot ulcer. Condition or disease Intervention/treatment Diabetes Mellitus, Type 2 Drug: Propolis spray Detailed Description: They will be invited to enter the study, at no cost, to 72 patients seen in the Specialty Clinic of the Regional Hospital of Talca, who have a history of diabetic feet with ulcers and who

2018 Clinical Trials

197. Iron Reduction by Phlebotomy to Improve Diabetes Control

Health Sciences Collaborator: University of North Carolina, Chapel Hill Information provided by (Responsible Party): Wake Forest University Health Sciences Study Details Study Description Go to Brief Summary: This is a treatment study to determine if reducing the body's iron stores by blood donation will improve diabetes control and other problems associated with diabetes such as fatty liver disease. Condition or disease Intervention/treatment Phase Iron Diabetes Nonalcoholic Fatty Liver Procedure (...) Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Wake Forest University Health Sciences: Iron Reduction Phlebotomy Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Fatty Liver Non-alcoholic Fatty Liver Disease Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Liver Diseases

2018 Clinical Trials

198. Glycemic Control and Treatment Satisfaction in Children With Type 1 Diabetes Using Insulin Pumps

), frequency of technical difficulties, skin reactions, discontinuation rate, glycated hemoglobin (HBA1C), mean glucose, total daily insulin dose (TDD) , pump setting parameters and BMI. Condition or disease T1DM Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 60 participants Observational Model: Case-Only Time Perspective: Prospective Official Title: Glycemic Control and Treatment Satisfaction in Children With Type 1 Diabetes Using Insulin Pumps Actual (...) Posted: October 5, 2018 Last Update Posted: October 5, 2018 Last Verified: October 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: Yes Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus, Type 1 Diabetes Mellitus Glucose Metabolism Disorders Metabolic

2018 Clinical Trials

199. Intensive Versus Conventional Glycemic Control in Diabetic Foot Ulcer Healing

Device Product: No Keywords provided by Ashu Rastogi, Postgraduate Institute of Medical Education and Research: Diabetic foot ulcer Intensive glycemic control Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Diabetic Foot Foot Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases Insulin Insulin, Globin Zinc (...) with the primary aim of wound healing in patients of diabetic foot ulcer on either intensive glycemic treatment or conventional (pre-existing) glycemic treatment. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Drug: Insulin Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose

2018 Clinical Trials

200. G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

is conducted 2-7 days following administration of the final dose of study drug. Condition or disease Intervention/treatment Phase Insulin Hypoglycemia Type 1 Diabetes Mellitus Severe Hypoglycemia Drug: G-Pen Drug: Novo Glucagon Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 122 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title (...) First Posted : November 12, 2018 Last Update Posted : February 15, 2019 See Sponsor: Xeris Pharmaceuticals Collaborator: Empiristat, Inc. Information provided by (Responsible Party): Xeris Pharmaceuticals Study Details Study Description Go to Brief Summary: This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime clinical research center (CRC) visits with random assignment

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>